INVESTIGATION OF ISCHEMIA-MODIFIED ALBUMIN IN ACUTE ISCHEMIC STROKE

Ischemia modified albumin (IMA) is a new serum biomarker of ischemic diseases, especially myocardial ischemia. Now it has been extended in the diagnosis of stroke. In this study we aimed to evaluate the value of IMA in the diagnosis of acute ischemic stroke. 126 patients were enrolled in this study. 78 individuals were diagnosed as ischemic stroke via MRI. The other 48 patients served as control group, consisting of 5 epilepsia, 12 hypokalemic periodic paralysis, 14 transient ischemic attack (TIA), 9 subarachnoid hemorrhage, 6 parkinson disease, and 2 postural hypotension. IMA was detected with ACB (albumin cobalt binding) test. Receiver operator characteristic (ROC) curve was analyzed and the cutoff value, the sensitivity and specificity of the cutoff value were calculated. The mean serum IMA value was 93.30 +/- 15.20 U/ml in the stroke group, as that of control group was 75.65 +/- 13.05 U/ml (P<0.001, 95%CI, 12.42, 22.89). When the cut-off threshold derived from the receiver operating characteristics (ROC) curve was determined as 87.3 U/ml, the sensitivity of IMA for the diagnosis of acute ischemic stroke was 67.9%, and the specificity was 79.2%. The calculated positive predictive value (PPV) and negative predictive value (NPV) were 0.84 and 0.60, respectively. IMA has high specificity and positive predictive value and is a useful diagnostic biomarker for acute ischemic stroke